Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients.

International journal of molecular sciences - 23 Aug 2022

Ryu Woo Kyung, Oh Sekyung, Lim Jun Hyeok, Lee Seung Jae, Shin Hyun-Tae, Ryu Jeong-Seon

Abstract excerpt

Circulating tumor DNA (ctDNA) has been utilized to monitor the clinical course of patients of non-small-cell lung cancer (NSCLC) who receive therapies targeting druggable mutations. However, despite providing valuable information on how NSCLC would naturally progress, the clinical utility of ctDNA for clinical-course monitoring and prediction of treatment-naïve NSCLC patients without druggable mutations remain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Lung Neoplasms

Share to Mutation

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 36076922
DOI: 10.3390/ijms23179527
PMCID: PMC9455735

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients.PMID 36076922Read ↗

Clinical Implication of Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.Semantic proximity Read ↗

Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.Semantic proximity Read ↗

Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

Role of circulating-tumor DNA analysis in non-small cell lung cancer.Semantic proximity Read ↗

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.Semantic proximity Read ↗

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectivesSemantic proximity Read ↗

Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Semantic proximity Read ↗

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.